2025-02-23T00:03:50-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: Query fl=%2A&wt=json&json.nl=arrarr&q=id%3A%22irk-123456789-137976%22&qt=morelikethis&rows=5
2025-02-23T00:03:50-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: => GET http://localhost:8983/solr/biblio/select?fl=%2A&wt=json&json.nl=arrarr&q=id%3A%22irk-123456789-137976%22&qt=morelikethis&rows=5
2025-02-23T00:03:50-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: <= 200 OK
2025-02-23T00:03:50-05:00 DEBUG: Deserialized SOLR response
Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia

Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia

Background: Imatinib is tyrosine kinase inhibitor (TKI) and as a targeted anti-cancer agent has significantly changed chronic myeloid leukemia (CML) prognosis and patient survival. Currently TKI is the main therapy in CML Philadelphia chromosome-positive (Ph-positive) cases. When generics of imatini...

Full description

Saved in:
Bibliographic Details
Main Authors: Lejniece, S., Udre, I., Rivkina, A.
Format: Article
Language:English
Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2017
Series:Experimental Oncology
Subjects:
Original contributions
Online Access:http://dspace.nbuv.gov.ua/handle/123456789/137976
Tags: Add Tag
No Tags, Be the first to tag this record!
id irk-123456789-137976
record_format dspace
spelling irk-123456789-1379762018-06-18T03:12:40Z Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia Lejniece, S. Udre, I. Rivkina, A. Original contributions Background: Imatinib is tyrosine kinase inhibitor (TKI) and as a targeted anti-cancer agent has significantly changed chronic myeloid leukemia (CML) prognosis and patient survival. Currently TKI is the main therapy in CML Philadelphia chromosome-positive (Ph-positive) cases. When generics of imatinib appeared in the pharmaceuticals market, reimbursement policies in many countries switched to using generics or encouraged use of generic imatinib to lower the expenses. Cost savings were substantial; however, for doctors and CML patients the efficacy, safety and quality of generic imatinib were an issue of concern. Objective: Since the global number of CML patients, who in the future will have to switch from original imatinib to generic imatinib, is high, the aim of study was to monitor, whether during 24 months of generic imatinib usage patients maintain the achieved major molecular response (MMR) or whether the treatment results are inferior. Methods: We conducted a retrospective study, which included CML patients, who were above 18 years of age and who until May 2013 had used at least for 2 years (24 months) the original imatinib, and following that used at least for 24 months one of the generic imatinib medicines. In 2013, before switching to generic imatinib, all patients had reached MMR in accordance with European LeukemiaNet (ELN) Guidelines. Every three months blood count, BCR-ABL fusion gene (BCR-ABL), biochemical analysis and side effect were monitored. Results: Our study proved that CML patients, who had achieved MMR by original imatinib therapy, retained MMR during 24 months of generic imatinib therapy. Nobody was switched to second line generation TKI. During observation period neither haematological, nor non-hematological toxicity was found. Conclusion: Our study proved that CML patients, who had achieved MMR by original imatinib therapy, retained MMR during 24 months of generic imatinib therapy. This demonstrates that generic imatinib is not inferior to original imatinib. As to expenses, the annual costs of generic imatinib are lower by 96%, which is a significant benefit to health-care financing. 2017 Article Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia / S. Lejniece, I. Udre, A. Rivkina // Experimental Oncology. — 2017 — Т. 39, № 2. — С. 151–154. — Бібліогр.: 14 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/137976 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Original contributions
Original contributions
spellingShingle Original contributions
Original contributions
Lejniece, S.
Udre, I.
Rivkina, A.
Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia
Experimental Oncology
description Background: Imatinib is tyrosine kinase inhibitor (TKI) and as a targeted anti-cancer agent has significantly changed chronic myeloid leukemia (CML) prognosis and patient survival. Currently TKI is the main therapy in CML Philadelphia chromosome-positive (Ph-positive) cases. When generics of imatinib appeared in the pharmaceuticals market, reimbursement policies in many countries switched to using generics or encouraged use of generic imatinib to lower the expenses. Cost savings were substantial; however, for doctors and CML patients the efficacy, safety and quality of generic imatinib were an issue of concern. Objective: Since the global number of CML patients, who in the future will have to switch from original imatinib to generic imatinib, is high, the aim of study was to monitor, whether during 24 months of generic imatinib usage patients maintain the achieved major molecular response (MMR) or whether the treatment results are inferior. Methods: We conducted a retrospective study, which included CML patients, who were above 18 years of age and who until May 2013 had used at least for 2 years (24 months) the original imatinib, and following that used at least for 24 months one of the generic imatinib medicines. In 2013, before switching to generic imatinib, all patients had reached MMR in accordance with European LeukemiaNet (ELN) Guidelines. Every three months blood count, BCR-ABL fusion gene (BCR-ABL), biochemical analysis and side effect were monitored. Results: Our study proved that CML patients, who had achieved MMR by original imatinib therapy, retained MMR during 24 months of generic imatinib therapy. Nobody was switched to second line generation TKI. During observation period neither haematological, nor non-hematological toxicity was found. Conclusion: Our study proved that CML patients, who had achieved MMR by original imatinib therapy, retained MMR during 24 months of generic imatinib therapy. This demonstrates that generic imatinib is not inferior to original imatinib. As to expenses, the annual costs of generic imatinib are lower by 96%, which is a significant benefit to health-care financing.
format Article
author Lejniece, S.
Udre, I.
Rivkina, A.
author_facet Lejniece, S.
Udre, I.
Rivkina, A.
author_sort Lejniece, S.
title Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia
title_short Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia
title_full Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia
title_fullStr Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia
title_full_unstemmed Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia
title_sort generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2017
topic_facet Original contributions
url http://dspace.nbuv.gov.ua/handle/123456789/137976
citation_txt Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia / S. Lejniece, I. Udre, A. Rivkina // Experimental Oncology. — 2017 — Т. 39, № 2. — С. 151–154. — Бібліогр.: 14 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT lejnieces genericimatinibinthetreatmentofchronicmyeloidleukemiatwoyearsexperienceinlatvia
AT udrei genericimatinibinthetreatmentofchronicmyeloidleukemiatwoyearsexperienceinlatvia
AT rivkinaa genericimatinibinthetreatmentofchronicmyeloidleukemiatwoyearsexperienceinlatvia
first_indexed 2023-10-18T21:16:59Z
last_indexed 2023-10-18T21:16:59Z
_version_ 1796152398272528384

Similar Items